Ruxolitinib Adverse Event Data and Strategies for Managing Side Effects
Pashna Munshi, MD, provides an overview of adverse event data from the REACH3 trial of ruxolitinib in patients with steroid-refractory cGVHD and discusses management of patients’ side effects in clinical practice.
Case: A 58-Year-Old Man With Moderate Steroid-Refractory Chronic Graft-Versus-Host Disease
Initial Presentation
- A 58-year-old man previously underwent myeloablative conditioning and an allogeneic PBSC transplant for acute lymphocytic leukemia
- Received tacrolimus and methotrexate for GVHD prophylaxis
- At 10 months post-transplant, patient developed moderate muscle and joint pain with decreased range of motion, mild erythematous rash on cheeks
First-line Treatment
- Patient received topical steroid cream for rash, and was started on oral prednisone at 1 mg/kg/day
- After 4 weeks of treatment, the patient’s rash resolved but muscle/joint pain continued
Second-line Treatment
- Patient is now receiving ruxolitinib 10 mg orally twice daily, alongside 1 mg/kg/day steroids
Recent Videos
Related Content
